Documents and emails released this week in a lawsuit in U.S. District Court in Boston suggest that Pfizer's marketers urged the suppression of medical studies that reached unfavorable conclusions
about the effectiveness of Neurontin, which the FDA originally approved as an anti-seizure treatment for epilepsy and in 2002 for one kind of pain related to shingles.
The papers suggest
that Pfizer's marketers influenced the drug's scientific record to boost sales at least until 2003 by declining to release or altering the conclusions of studies that found no beneficial effect from
Neurontin for various off-label conditions.
Read the whole story at The Wall Street Journal »